Building a great team is hard—building one where people feel they truly belong is even harder. This week, Talus Bio’s Michelle Briscoe joined a panel hosted by Women In Bio - Seattle and Deloitte on fostering a culture of belonging in the life sciences. Michelle’s leadership has helped the company prioritize diversity and inclusion as we’ve grown, ensuring all employees continue to feel valued and supported as we scale. The panel brought together voices from across Seattle’s biotech scene with leaders from the Allen Institute, Mirador Therapeutics, and Geron Corporation. Michelle shared a few of her guiding principles for ensuring our team always feels safe and supported: ▶️ Acknowledge what you don't know. Curiosity reveals the blind spots where people get left behind ▶️ Benefits aren't checkboxes. They need to reflect actual team needs with language that includes everyone ▶️ Recognition matters, but how you do it matters more ▶️ Leave room for mistakes. Inclusion falls apart when people are afraid to learn and grow These are the tough conversations that keep moving Seattle life sciences forward. Thanks to Women in Bio and Deloitte for bringing us together to share strategies for creating inclusive workplaces that drive innovation and success.
Talus Bio
Biotechnology Research
Seattle, WA 4,044 followers
Gene regulator profiling in live cells for drug development
About us
Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics. As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery: - Developing internal programs against previously undruggable gene regulators in cancers with poor standard of care - Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs
- Website
-
http://talus.bio
External link for Talus Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Seattle, WA
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
550 17th Ave
Suite 550
Seattle, WA 98122, US
Employees at Talus Bio
-
Gavin Hirst
Drug Discovery Executive Leader | Medicinal Chemist | Consultant
-
Michelle Briscoe
Chief Operating Officer and Chief Financial Officer at Talus Bio | Co-founder & Board Member of OUTbio - Seattle 🏳️🌈 | Board Member of HBA -…
-
Christopher Joyce
Business Development at Talus Bio
-
Stephen (Steve) Letrent
Clinical Development Leader. Executive. Board Member.
Updates
-
The Talus Bio team (Alex Federation, Gaelle Mercenne and Brian McEllin) is excited to present 3 posters at #AACR in Chicago. Alex will present how our platform unlocks “undruggable” transcription factors for small molecule development by measuring changes in gene control. These data feed a closed-loop AI system that discovers and prioritizes drug-like modulators for driver transcription factors in cancer. Posters from Gaelle and Brian will show how this technology is already delivering: lead molecules with strong preclinical efficacy in non-small cell lung cancer and chordoma, and a new first-in-class compound targeting an “undruggable” transcription factor in resistant prostate cancer. Attending AACR in Chicago? Stop by the posters to learn more about how Talus Bio is unlocking “undruggable” transcription factors for critical unmet needs. Flip through the deck below for the poster details:
-
The voting deadline is approaching! The Talus Bio team is a proud finalist for GeekWire’s 2025 Health Innovation of the Year Award. We’re developing new molecules to make “undruggable” transcription factors a thing of the past. It’s a true team effort as we deploy Talus Bio’s innovative technologies to advance these molecules towards patients in need. Help us show a little love for the team. Don’t miss your chance to vote for Talus Bio in the 2025 GeekWire Awards 🔽 https://lnkd.in/gNi5MVeh
-
-
The toughest challenges in medicine require the brightest global minds working side by side. Connect with Christopher Joyce next week at BIO-Europe Spring in Milan to discuss how Talus Bio unlocks “undruggable” transcription factors. We’ll share the latest on how innovative proteomics is powering AI-guided discovery for the field’s most valuable targets. If you’ll be in Milan next week, connect with Chris to discuss how we can advance the field together.
Excited to attend BIO-Europe Spring on March 17–19, 2025! If you're interested in exploring how we can drug previously undruggable transcription factors, let’s connect in Milan! #BIOEuropeSpring Informa Connect
-
-
Our stellar scientists are all smiles as finalists for GeekWire's Health Innovation of the Year Award, alongside esteemed research institutions, health tech startups, and biotech companies. We're thankful for the opportunity to tackle the hardest problems in transcription factor therapeutics, rethink what's possible, and ensure that our science translates into impact that will benefit the patients who need it most. Vote now for Talus Bio in the 2025 GeekWire Awards! https://lnkd.in/gNi5MVeh
-
-
Talus Bio is looking for a Lab and Office Operations Associate to join our team full-time on-site in our Seattle location. This person will work directly in the Operations department of Talus Bio, reporting to the Laboratory Operations Manager, and will be naturally curious, results-driven, and eager to work in a small preclinical biotech environment. This unique role will be ideally suited for someone who has some limited experience working in a biological laboratory, a desire to pursue a career in laboratory operations, and a passion for the administrative and social planning work that supports a stellar team of scientists! Apply at https://lnkd.in/gQ6Mztmm.
Chief Operating Officer and Chief Financial Officer at Talus Bio | Co-founder & Board Member of OUTbio - Seattle 🏳️🌈 | Board Member of HBA - Seattle Chapter
Do you have a bit of cell culture experience? Do you love planning parties? Are you passionate about creating a safe and supportive work environment? I'm looking for an exceptional entry-level operations person to join my team! This is a bit of a unicorn role, where you do a little of everything in the lab and around the office.
-
Talus Bio’s Alex Federation will be in Boston for the 1st Termeer Foundation Summit: CEOs for Cures this week. He’ll be meeting with CEOs from across the biotech and life sciences industry in the spirit of the event to “connect and empower the world of healthcare innovators until every patient has a cure.”
Co-Founder and CEO at Talus Bio - nothing is "undruggable" - therapeutics historically intractable transcription factors in cancer and beyond
When people talk about visionary CEOs, people often think of Steve Jobs, Bill Gates or Josh Boger. But for me, Henri Termeer stands apart. At Genzyme, he built a playbook for how to bring life-changing medicines to patients who had been overlooked, even when the market didn’t exist yet. That meant innovating in science and in policy, finding new ways to make drug development viable when conventional wisdom said it wasn’t. But his greatest legacy is the people. He believed that the best way to develop cures was to build the best teams. He didn’t just lead; he mentored—investing in individuals, challenging them to rise and meet the challenge ahead, and shaping a generation of biotech leaders who continue to carry that mission forward today. I’m honored to be part of this legacy and to connect at The Termeer Foundation Summit this week with CEOs who share the same drive: to take on the hardest problems, to rethink what’s possible, and to make sure that science translates into impact where it’s needed most.
-
Talus Bio’s Lindsay Pino, Sebastian Paez, and Andrea Gutierrez presented new methods for high-throughput, low-input quantitative proteomics in transcription factor drug discovery at the US HUPO in Philadelphia. Their presentations focused on how Talus Bio developed the TF-Scan platform for transcription factor drug discovery using high-sensitivity mass spectrometry methods that quantify chromatin-binding proteins from as few as 50,000 cells. They also introduced timsQuery – https://lnkd.in/geg6MZM8 – an open-source Python package for trapped ion mobility spectrometry (TIMS) data from Bruker Daltonics, improving large-scale proteomics data extraction and interpretation. Take a look at the team in action:
-
-
A breakthrough drug doesn’t guarantee a return on investment for the drug’s investors. Revumenib looks like a game-changer for certain acute leukemias, giving patients with few alternatives a new therapeutic option. But the addressable market is small, and investors are increasingly shying away from niche indications in favor of larger, more predictable returns. Now, the drug’s future depends on its ability to expand into broader indications, differentiate from competitors, and prove it can scale—not just scientifically, but financially. Alex Federation breaks down the next chapter for revumenib—and what it means for the future of rare disease drug development in today’s shifting biotech landscape. Read more: https://lnkd.in/gk4Rj25Z
-
-
Talus Bio reposted this
Talus Bio's William Fondrie just gave a keynote at the EuBIC Mass Spectrometry Developers Meeting diving into how open-source tools and AI are driving the next wave of innovation in proteomics. Great to see a room full of people pushing the field forward through hackathons and real collaboration. Big thanks to the organizers for making it happen. More on the event here: https://lnkd.in/g4zp_HX2 Thanks to Ralf Gabriels and Magnus Palmblad for the photos
-